Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Guardion Health Sciences Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Guardion Health Sciences şirketinin toplam hissedar öz sermayesi $26.5M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $28.2M ve $1.7M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$12.95m
Eşitlik	US$26.49m
Toplam yükümlülükler	US$1.73m
Toplam varlıklar	US$28.23m

Son finansal sağlık güncellemeleri

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 0QTA 'nin kısa vadeli varlıkları ( $17.8M ) kısa vadeli yükümlülüklerini ( $1.7M ) aşıyor.

Uzun Vadeli Yükümlülükler: 0QTA un uzun vadeli yükümlülüğü bulunmamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 0QTA borçsuzdur.

Borcun Azaltılması: 0QTA şirketinin 5 yıl önce borç/öz sermaye oranı 7.9% iken borcu yok.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: 0QTA şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: 0QTA serbest nakit akışı her yıl % 26 1.7 yıl yetecek nakit akışına sahip olacaktır.

Guardion Health Sciences Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Guardion Health Sciences Expects the Official Delisting of its Common Stock to be Effective October 21, 2024

Guardion Health Sciences Regains Compliance with Nasdaq Continued Listing Requirements

Guardion Health Sciences Regains Compliance with Nasdaq Minimum Bid Price Rule

Guardion Health Sciences Announces 1-For-6 Reverse Stock Split to Comply with the $1.00 Per Share Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market

Nasdaq Grants Guardion Health Sciences an Extension to March 15, 2021 to Regain Compliance with the $1.00 Minimum Bid Price Rule

Recent updates

Guardion Health Sciences Expects the Official Delisting of its Common Stock to be Effective October 21, 2024

Guardion Health Sciences, Inc. Appoints Mark Goldstone as Interim Chief Executive Officer, Effective as of October 18, 2024

Guardion Health Sciences, Inc. Declares Dividend, Payable on September 23, 2024

Doctor's Best, Inc. agreed to acquire Activ Nutritional, LLC. from Guardion Health Sciences, Inc. (NasdaqCM:GHSI) for $17.2 million.

Guardion Health Sciences, Inc., Annual General Meeting, Nov 21, 2023

Guardion Health Sciences, Inc. Announces Executive Changes

Guardion Health Sciences, Inc. Announces Executive Changes

Guardion Health Sciences Regains Compliance with Nasdaq Continued Listing Requirements

Guardion Health Sciences, Inc. Announces Clinical Results Indicating that Viactiv® Omega Boost™ Gel Bites Increase Omega-3 Levels in Just 4 weeks

Guardion Health Sciences, Inc., Annual General Meeting, Jun 16, 2022

Guardion Health Sciences, Inc. Announces New Viactiv® Omega Boost Gel Bites Now Available for Purchase Via Viactiv® Shopify Store

Guardion Health Sciences, Inc. Launches New Viactiv® Omega BOOST™ Passion Fruit Flavored Gel Bites

Guardion Health Sciences to Wind Down VectorVision Business Operations and Focus on Exploiting VectorVision Intellectual Property

Guardion Health Sciences, Inc. (NasdaqCM:GHSI) completed the acquisition of Activ Nutritional, LLC from Adare Pharmaceuticals, Inc.

Guardion Health Sciences, Inc. (NasdaqCM:GHSI) entered into an Equity Purchase Agreement to acquire Activ Nutritional, LLC from Adare Pharmaceuticals, Inc. for $26 million.

Guardion Health Sciences, Inc. Initiates Placebo-Controlled Clinical Trial Involving Proprietary GlaucoCetin® Product

Guardion Health Sciences Regains Compliance with Nasdaq Minimum Bid Price Rule

Guardion Health Sciences Announces 1-For-6 Reverse Stock Split to Comply with the $1.00 Per Share Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market

New 90-day high: €1.06

Guardion Health Sciences Receives Regulatory Product Registration Approval for Second Immune Support Dietary Supplement Designed and Produced by Guardion Health Sciences

Nasdaq Grants Guardion Health Sciences an Extension to March 15, 2021 to Regain Compliance with the $1.00 Minimum Bid Price Rule

New 90-day high: €0.77

HO WAH GENTING BERHAD Appoints Guardion Health Sciences, Inc to Design and Manufacture an Exclusive Custom Immune Support Nutraceutical Formula

Guardion Health Sciences, Inc. Appoints Bret Scholtes as Chief Executive Officer Commencing January 6, 2021

New 90-day high: €0.26

Guardion Health Sciences Announces Development of New Vision/Energy Support Drink – EPIQ-V

New 90-day high: €0.23

Third quarter 2020 earnings released: US$0.024 loss per share

Guardion Health Sciences Announces Investigator-Initiated Clinical Trial of Lumega-Z

New 90-day low - €0.23

First half earnings released

Guardion Health Sciences, Inc. to Report Q2, 2020 Results on Aug 12, 2020

New 90-day low - €0.34

New 90-day low - €0.35

Guardion Health Sciences, Inc.(NasdaqCM:GHSI) dropped from Russell Microcap Index

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin